Objective To investigate the effect of aspirin and cilostazol on interleukin-6 (IL-6) and high sensitive C reactive protein (hsCRP) and platelet-activating factor acetylhydrolase (PAF-AH) in acute coronary syndrome (ACS) patients and the difference between them.

Methods 72 patients with ACS were randomly divided into two groups: the aspirin group (n=34) and cilostazol group (n=38). All patients were given routine therapy including rest, oxygen inhaling, anticoagulating, reducing blood lipid levels, controlling the blood pressure. The patients in the aspirin group were given aspirin 0.1 g every day in addition. The patients in the cilostazol group were given cilostazol 0.1 g twice a day underlying the routine therapy. The course of treatment was 4 weeks. Observe the IL-6 and hsCRP and PAF-AH in serum and on peripheral blood mononuclear cells of the patients before and after treatment.

Result The basic characteristics of the two groups were identical (p>0.05). The content of IL-6 and hsCRP were all significantly decreased after therapy (p<0.05), and the content of PAF-AH were significantly increased after therapy (p<0.05). The content of IL-6 (25.9±7.5 vs 20.3±9.8 pg/ml) and hsCRP (9.5±2.1 vs 6.1±1.9 g/l) in aspirin group (after treatment) were significantly higher than those in cilostazol group (after treatment)(p<0.05), and PAF-AH (27.2±5.6 vs 36.8±2.6 μmolċmin⁻¹l⁻¹) in aspirin group (after treatment) were significantly lower than those in cilostazol group (after treatment) (p<0.05).

Conclution Aspirin and cilostazol can decrease IL-6 and hsCRP level and increase PAF-AH level in ACS patients. And cilostazol is more effective than aspirin to inhibit the inflammatory response in ACS patients.